Single Dose Oral Treatment for Vaginal Trichomoniasis and Bacterial Vaginosis. A Comparison of Nitazoxanide and Metronidazole

GRUPO FARMAKONSUMA S.A.,0 个研究点目标入组 0 人开始时间: 2005年8月3日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•Women aged 18 to 48 years who give their consent in writing and with a diagnosis of vaginal trichomoniasis, bacterial vaginosis or both, proven by clinical findings, defined by the researcher, fresh smear of positive vaginal secretion and 3 or more criteria of Amsel positive, respectively.

•1) Patients under 18 years and over 48 years of age.
•2) Patients with suspected concomitant diagnosis of mycosis
•vaginal or other pathology not considered in the inclusion criteria.
•3) Patients in which a breach is foreseen in the
•follow up of the study.
•4) Patients who do not sign informed consent.
•5) Patients with concomitant diseases that, in the opinion of the researcher, discourage their inclusion in the study.
•6) Patients with known hypersensitivity to imidazoles.
•7) Patients with suspected blood dyscrasias.
•8) Patients with suspicion or history of deterioration of the
•liver or kidney function.
•9) Patients with suspected pregnancy or breast-feeding.
•10) Patients with suspected acute or chronic disease of the
•11) Patients whose pathological situation may interfere with the
•development of the study.
•12) Patients who use concomitant coumarins and / or
•13) Patients with NSAID use up to seven days before the
•administration of the treatment.
•14) Patients who are consuming at the time of the study
•some antiparasitic medication, antibiotic or whatever
•Consumed up to 15 days before its inclusion.
•15) Patients with suspected digestive pathology (gastritis,
•hepatitis, ulcer, etc.).
•16) Patients with more than one sexual partner reported.
•17) Patients with BMI less than 18.85 and greater than 26.9.

发起方

GRUPO FARMAKONSUMA S.A.,